Ajay Aggarwal, MD

Aclaris Therapeutics, Inc.
Wellesley, MA, United States

None

Disclosure information not submitted.

Presentation(s):

• 0311: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zunsemetinib, an Investigational Oral MK2 Inhibitor, at 80 Mg and 120 Mg Twice Daily Dose Levels in Healthy Subjects

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time